Stuart Therapeutics provides acknowledged leaders within the growth and commercialization of therapeutic merchandise in ophthalmology.
STUART, Florida., December 22, 2024 /PRNewswire/ — Stuart Therapeutics in the present day introduced the appointment of Tracy Valorie And Jason Werner to the corporate’s board of administrators, bringing the overall variety of board members to 5. These new administrators will occupy the positions beforehand held by Robert O. BarattaMD, died all of the sudden within the third quarter of this 12 months, and retired U.S. Consultant Diane Black, Registered Nursewho not too long ago resigned from his place on the corporate’s board of administrators.
Tracy Valorie is a strategic enterprise guide and proprietor of ™V Associates LLC Since July 2019. Ms. Valorie has 30 years of expertise within the pharmaceutical and biotechnology business. Ms. Valorie served as senior vice chairman and normal supervisor of WE pharmaceutical and surgical actions of Bausch + Lomb July 2012 has Could 2019. Earlier than becoming a member of B+L in 2012, Ms. Valorie held the place of gross sales supervisor of ophthalmology at Pfizer Inc. (NYSE:NYSE:) the place she had international accountability for the ophthalmology manufacturers in addition to accountability for mid-stage portfolio enterprise growth and long-term strategic planning. She is at present a guide or board member of a number of start-ups and was not too long ago appointed to the board of administrators of Administrators of the Glaucoma Analysis Basis (GRF). Ms. Valorie holds a grasp’s diploma in enterprise administration from Rensselaer Polytechnic Institute and a Bachelor of Science in Molecular Biology from College of Connecticut has Storrs, Connecticut.
Jason Werner at present serves as Govt Chairman of Sightstream Biotherapeutics, a biotechnology firm targeted on the event of regenerative therapies in ophthalmics and is a member of the board of administrators of InflammX Therapeutics. As well as, Mr Werner was a director of Alimera (NASDAQ:) because the second quarter of 2023 earlier than becoming a member of the Alimera administration group within the fourth quarter of 2023 and subsequently serving to to guide the corporate via its latest sale to ANI Pharma within the fourth quarter of 2024 . Mr Werner Beforehand, he co-founded and served as COO of Eyevance Prescribed drugs from the creation of the corporate till its sale Santen Prescribed drugs Ltd. He has additionally held numerous enterprise growth and company technique roles at firms resembling Solar Pharma, Nicox (EPA:) SA and Encourage pharmaceutical merchandiseall within the subject of ophthalmology. Mr Werner obtained his BS in Enterprise Administration from the College of New Hampshire.
“We’re excited concerning the alternative to welcome Tracy and Jason as members of our board of administrators and senior advisors to Stuart Therapeutics as we transfer to our subsequent stage of creating and commercializing therapeutic merchandise in ophthalmology,” declared Eric Smurf, Stuart Chairman and CEO. “Our group will profit from the profitable experiences she brings to our group. We might additionally like to acknowledge the contributions of our buddy and co-founder Bob BarattaMD, and Diane Black, Registered Nursewho’ve been instrumental in guiding the corporate via its formative phases, and we want Diane properly in her future endeavors.
“I’m delighted to affix the Stuart Therapeutics Board of Administrators. The chance to contribute to such an progressive biotechnology firm, on the forefront of breakthrough therapies, is actually thrilling. I look ahead to collaborating with an unimaginable group, serving to to information the corporate because it grows. seeks to make a significant affect on the lives of sufferers recognized with underserved ophthalmic issues,” mentioned Tracy Valorie.
Jason Werner mentioned: “That is an thrilling time for Stuart Therapeutics with key growth and pipeline milestones on the horizon. I look ahead to working alongside Tracy and Eric and the remainder of the gifted group to make sure these new therapies are delivered to sufferers whereas maximizing shareholder worth for Stuart and its buyers.”
About Stuart Therapeutics, Inc.
Stuart Therapeutics, Inc. is a clinical-stage ophthalmology therapeutic growth firm, primarily based in Stuart, Florida. The corporate’s lead asset, ST-100, is within the last phases of its Part 3 medical trial, with a readout anticipated within the first quarter of 2025. Stuart additionally develops cutting-edge packages in retinal illnesses and myopia and has a growth partnership via a neuroprotection license in glaucoma with Glaukos Corp. (NYSE:). of Aliso Viejo, California.
Media Contact:
Eric Smurf
President and CEO
eric@stuarttherapeutics.com
206-228-2781
www.stuarttherapeutics.com
